Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.57 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368664 | 0.89 | RPS6KB2 (0.57) | RPS6KB2KCNH2MAPTRAB9ASLC6A9 | |
| SCHEMBL8190730 | 0.80 | KCNH2 (0.44) | RPS6KB2TNFRSF1AKCNH2MAPTRAB9A | |
| SCHEMBL8190732 | 0.79 | KCNH2 (0.42) | RPS6KB2TNFRSF1AKCNH2SLC6A9HSD17B10 | |
| SCHEMBL14082889 | 0.76 | SMN1; SMN2 (0.66) | MAPTRAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL153244 | 0.75 | DYRK1A (0.53) | RPS6KB2KCNH2MAPTRAB9ASLC6A9 | |
| SCHEMBL2692579 | 0.72 | CA12 (0.59) | MAPTRAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL29629010 | 0.72 | PTGS2 (0.58) | MAPTRAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL9784218 | 0.72 | CTNNB1 (0.50) | RPS6KB2KCNH2MAPTRAB9ASLC6A9 | |
| SCHEMBL22162812 | 0.72 | CA12 (0.58) | MAPTRAB9AHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL25093334 | 0.71 | SMN1; SMN2 (0.44) | MAPTRAB9AHSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373262-B1 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | NOVARTIS AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | FUJIMOTO ROGER AKI (US) | 2004-11-25 | — | — | US | disclosed |
| EP-1373262-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | Novartis AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| WO-2002072577-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS. | NOVARTIS AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0948489-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998027069-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | MMP9, MMP1, MMP13 | RPS6KB2 3803/4885TNFRSF1A 627/4885KCNH2 2158/4885 |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | MMP1, MMP9, MMP13 | RPS6KB2 4041/4885TNFRSF1A 686/4885KCNH2 2411/4885 |
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP1, MMP2, TNF | RPS6KB2 2264/4885TNFRSF1A 22/4885KCNH2 3113/4885 |
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | RPS6KB2 2196/4885TNFRSF1A 22/4885KCNH2 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.